Inflammation in the oral cavity has far-reaching effects on blood vessels and nerves, leading to serious health implications.
Targeted Attack on Periodontitis Pathogen
Researchers at the Fraunhofer Institute for Cell Therapy and Immunology (IZI) have identified a new substance: Guanidinoethylbenzylamino Imidazopyridine Acetate. This compound specifically targets the bacterium Porphyromonas gingivalis, which is the primary cause of gum inflammation.
Unlike broad-spectrum antibiotics or antiseptic mouthwashes, this new treatment aims to preserve healthy oral flora. The spin-off company, PerioTrap, has already launched a microbiome toothpaste. Additionally, a gel for professional dental cleaning and mouth rinses are currently in development. There is also interest in its potential within veterinary medicine.
The Financial Barriers to Dental Care
A recent U.S. study emphasizes the importance of such therapies. As part of the “All of Us” research program, scientists analyzed data from over 90,000 participants aged 55 and older. The findings revealed that individuals who forgo dental visits due to cost concerns have a significantly higher risk of heart failure, heart attacks, strokes, and dementia.
The authors estimate that 2% to 4% of these conditions could be prevented if financial barriers in dental care were removed. For diabetics, who already face heightened vascular risks, managing local inflammation becomes a critical preventative strategy.
The 90,000-person study illustrates that gum inflammation dramatically increases the risk of heart attacks and strokes. However, new pathways to protect oneself are emerging—without the need for costly dental visits.
Revolutionizing Diabetes Management
In parallel with advancements in oral health, late June saw significant innovations in diabetes therapy. The EMA committee CHMP has recommended the approval of “Onswik” (Insulin Efsitora alfa)—a weekly insulin for Type 2 diabetics. In England and Wales, Teplizumab, an immunotherapy that can delay the onset of Type 1 diabetes by up to three years, is available through the NHS.
A recent study suggests that consistent glucose stabilization in prediabetic patients can reduce the risk of heart attacks and strokes by 42%. Moreover, SGLT2 inhibitors and GLP-1 agonists have been associated with a reduction in Alzheimer’s disease risk by 43% and 33%, respectively.
However, not all hopes are fulfilled. A Cochrane review at the end of June evaluates the benefits of alpha-lipoic acid in diabetic polyneuropathy critically, concluding that dosages between 600 and 1800 mg per day did not yield clinically relevant improvements compared to placebo in three randomized trials with a total of 816 participants.
Enhanced Diagnostics and Increased Dental Clinics
For diabetics, inadequate inflammation control in the mouth could significantly elevate vascular risk. A new therapeutic agent specifically targets the periodontitis pathogen while preserving healthy oral flora.
The Jena University Hospital has developed a method for pathogen diagnostics using blood plasma. Utilizing nanopore sequencing of cell-free DNA, results can be obtained within twelve hours—even while an antibiotic therapy is ongoing. A pilot study with 18 patients demonstrated a match with clinical diagnoses in 16 cases, costing approximately 100 to 120 euros per sample.
On an infrastructural level, investment is heading towards increasing dental care capacity. In New York, $25 million has been allocated to specialized clinics for individuals with developmental disorders, with $5.5 million directed to the NYU Dental Center to expand its treatment capacity to over 3,300 patients a year.
